Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 2 days agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 22, 2008 | Fludarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUDARABINE PHOSPHATE FOR INJECTION USP (DIN 02293846) under ATC L01BB05 FLUDARABINE. Indications are not published… | DIN02293846 | withdrawnsource: Cancelled Post Marketsince Aug 1, 2018 | health-canada-dpd |
| Sep 10, 2008 | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION (DIN 02305526) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug… | DIN02305526 | withdrawnsource: Cancelled Post Marketsince Apr 30, 2018 | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 9, 2008 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as PRO-BICALUTAMIDE (DIN 02311038) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02311038 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 27, 2008 | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION (DIN 02305534) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug… | DIN02305534 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 30, 2008 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METOJECT (DIN 02304767) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database —… | DIN02304767 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 16, 2008 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOM-BICALUTAMIDE (DIN 02281139) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02281139 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 30, 2008 | Irinotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as IRINOTECAN HYDROCHLORIDE TRIHYDRATE INJECTION (DIN 02305143) under ATC L01CE02 IRINOTECAN. Indications are not… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 27, 2007 | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION, USP (DIN 02298783) under ATC L01BC05 GEMCITABINE. Indications are not published in the… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 20, 2007 | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE HYDROCHLORIDE FOR INJECTION (DIN 02302101) under ATC L01BC05 GEMCITABINE. Indications are not published… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 29, 2007 | Tamoxifen | Health Canada CA | cancer not stated in this record | Marketed in Canada as TAMOXIFENE - 20 (DIN 02296748) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product… | DIN02296748 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 17, 2007 | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as ELOXATIN (DIN 02296284) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug Product Database —… | DIN02296284 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 9, 2007 | Vinorelbine | Health Canada CA | cancer not stated in this record | Marketed in Canada as VINORELBINE TARTRATE FOR INJECTION (DIN 02271214) under ATC L01CA04 VINORELBINE. Indications are not published in the… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 13, 2007 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SPRYCEL (DIN 02293145) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see… | DIN02293145 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 5, 2007 | Erlotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARCEVA (DIN 02269007) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see… | DIN02269007 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 4, 2006 | Fludarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUDARABINE PHOSPHATE FOR INJECTION (DIN 02283859) under ATC L01BB05 FLUDARABINE. Indications are not published in… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 25, 2006 | Idarubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as IDAMYCIN PFS (DIN 02282496) under ATC L01DB06 IDARUBICIN. Indications are not published in the Drug Product Database… | DIN02282496 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 31, 2006 | Paclitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as ABRAXANE FOR INJECTABLE SUSPENSION (DIN 02281066) under ATC L01CD01 PACLITAXEL. Indications are not published in the… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 31, 2006 | Sorafenib | Health Canada CA | cancer not stated in this record | Marketed in Canada as NEXAVAR (DIN 02284227) under ATC L01EX02 SORAFENIB. Indications are not published in the Drug Product Database — see… | DIN02284227 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 22, 2006 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SUTENT (DIN 02280817) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see… | DIN02280817 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 30, 2006 | Interferon Beta-1a | Health Canada CA | cancer not stated in this record | Marketed in Canada as REBIF (DIN 02277492) under ATC L03AB07 INTERFERON BETA-1A. Indications are not published in the Drug Product Database… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 10, 2006 | Tositumomab | Health Canada CA | cancer not stated in this record | Marketed in Canada as BEXXAR THERAPY (DIN 02270471) under ATC V10XA53 TOSITUMOMAB/IODINE (131 I) TOSITUMOMAB. Indications are not published… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 28, 2006 | Mitoxantrone | Health Canada CA | cancer not stated in this record | Marketed in Canada as MITOXANTRONE INJECTION (DIN 02267535) under ATC L01DB07 MITOXANTRONE. Indications are not published in the Drug… | DIN02267535 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 10, 2006 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-BICALUTAMIDE (DIN 02270226) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02270226 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| approvedsource: Marketed |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Apr 30, 2018 |
| health-canada-dpd |
| Jun 27, 2008 | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as ELOXATIN (DIN 02296276) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug Product Database —… | DIN02296276 | withdrawnsource: Cancelled Post Marketsince Aug 4, 2016 | health-canada-dpd |
| Jun 27, 2008 | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as ELOXATIN (DIN 02296268) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug Product Database —… | DIN02296268 | withdrawnsource: Cancelled Post Marketsince Aug 3, 2016 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince May 19, 2017 |
| health-canada-dpd |
| May 27, 2008 | Panitumumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as VECTIBIX (DIN 02308487) under ATC L01FE02 PANITUMUMAB. Indications are not published in the Drug Product Database —… | DIN02308487 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince May 9, 2025 |
| health-canada-dpd |
| Apr 7, 2008 | Epirubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as EPIRUBICIN HYDROCHLORIDE FOR INJECTION (DIN 02301067) under ATC L01DB03 EPIRUBICIN. Indications are not published in… | DIN02301067 | withdrawnsource: Cancelled Post Marketsince Jan 18, 2019 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Aug 1, 2019 |
| health-canada-dpd |
| Jan 25, 2008 | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION, USP (DIN 02298775) under ATC L01BC05 GEMCITABINE. Indications are not published in the… | DIN02298775 | withdrawnsource: Cancelled Post Marketsince Aug 1, 2018 | health-canada-dpd |
| Jan 17, 2008 | Nelarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as ATRIANCE (DIN 02299925) under ATC L01BB07 NELARABINE. Indications are not published in the Drug Product Database —… | DIN02299925 | approvedsource: Marketed | health-canada-dpd |
| Jan 11, 2008 | Temsirolimus | Health Canada CA | cancer not stated in this record | Marketed in Canada as TORISEL (DIN 02304104) under ATC L01EG01 TEMSIROLIMUS. Indications are not published in the Drug Product Database —… | DIN02304104 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Aug 1, 2014 |
| health-canada-dpd |
| Dec 20, 2007 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as MYLAN-BICALUTAMIDE (DIN 02302403) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02302403 | withdrawnsource: Cancelled Post Marketsince Jan 9, 2017 | health-canada-dpd |
| Dec 17, 2007 | Paclitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as PACLITAXEL FOR INJECTION (DIN 02296624) under ATC L01CD01 PACLITAXEL. Indications are not published in the Drug… | DIN02296624 | withdrawnsource: Cancelled Post Marketsince Apr 6, 2021 | health-canada-dpd |
| Dec 3, 2007 | Mitoxantrone | Health Canada CA | cancer not stated in this record | Marketed in Canada as MITOXANTRONE INJECTION (DIN 02286300) under ATC L01DB07 MITOXANTRONE. Indications are not published in the Drug… | DIN02286300 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Aug 1, 2019 |
| health-canada-dpd |
| Nov 20, 2007 | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE HYDROCHLORIDE FOR INJECTION (DIN 02302098) under ATC L01BC05 GEMCITABINE. Indications are not published… | DIN02302098 | withdrawnsource: Cancelled Post Marketsince Aug 1, 2019 | health-canada-dpd |
| Nov 5, 2007 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-BICALUTAMIDE (DIN 02296063) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02296063 | withdrawnsource: Dormantsince May 14, 2023 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jul 27, 2011 |
| health-canada-dpd |
| Oct 29, 2007 | Tamoxifen | Health Canada CA | cancer not stated in this record | Marketed in Canada as TAMOXIFENE - 10 (DIN 02296721) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product… | DIN02296721 | withdrawnsource: Cancelled Post Marketsince Jul 27, 2011 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Nov 9, 2018 |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Apr 13, 2007 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SPRYCEL (DIN 02293137) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see… | DIN02293137 | approvedsource: Marketed | health-canada-dpd |
| Apr 13, 2007 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SPRYCEL (DIN 02293129) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see… | DIN02293129 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Oct 1, 2024 |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jun 30, 2026 |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Aug 2, 2006 | Anagrelide | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOM-ANAGRELIDE (DIN 02281287) under ATC L01XX35 ANAGRELIDE. Indications are not published in the Drug Product… | DIN02281287 | withdrawnsource: Cancelled Post Marketsince May 9, 2025 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jul 21, 2006 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as PHL-BICALUTAMIDE (DIN 02281163) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02281163 | withdrawnsource: Cancelled Post Marketsince Jul 21, 2006 | health-canada-dpd |
| Jul 21, 2006 | Anagrelide | Health Canada CA | cancer not stated in this record | Marketed in Canada as PHL-ANAGRELIDE (DIN 02281155) under ATC L01XX35 ANAGRELIDE. Indications are not published in the Drug Product… | DIN02281155 | withdrawnsource: Cancelled Post Marketsince Oct 26, 2009 | health-canada-dpd |
| Jul 14, 2006 | Histrelin | Health Canada CA | cancer not stated in this record | Marketed in Canada as VANTAS (DIN 02278383) under ATC L02AE05 HISTRELIN. Indications are not published in the Drug Product Database — see… | DIN02278383 | withdrawnsource: Cancelled Post Marketsince Apr 7, 2017 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jun 22, 2006 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SUTENT (DIN 02280809) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see… | DIN02280809 | approvedsource: Marketed | health-canada-dpd |
| Jun 22, 2006 | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SUTENT (DIN 02280795) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see… | DIN02280795 | approvedsource: Marketed | health-canada-dpd |
| Jun 19, 2006 | Interferon Beta-1a | Health Canada CA | cancer not stated in this record | Marketed in Canada as REBIF (DIN 02281708) under ATC L03AB07 INTERFERON BETA-1A. Indications are not published in the Drug Product Database… | DIN02281708 | withdrawnsource: Cancelled Post Marketsince Aug 9, 2013 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Aug 9, 2013 |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jul 31, 2014 |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jul 9, 2018 |
| health-canada-dpd |
| Mar 13, 2006 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as RATIO-BICALUTAMIDE (DIN 02277700) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02277700 | withdrawnsource: Cancelled Post Marketsince Sep 19, 2014 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Feb 8, 2006 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ BICALUTAMIDE (DIN 02276089) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02276089 | withdrawnsource: Cancelled Post Marketsince Aug 1, 2019 | health-canada-dpd |
| Feb 8, 2006 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-BICALUTAMIDE (DIN 02275589) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02275589 | approvedsource: Marketed | health-canada-dpd |
| Feb 7, 2006 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACT BICALUTAMIDE (DIN 02274337) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02274337 | withdrawnsource: Cancelled Post Marketsince Jul 11, 2018 | health-canada-dpd |
| Feb 1, 2006 | Irinotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION USP (DIN 02258218) under ATC L01CE02 IRINOTECAN. Indications are not published in… | DIN02258218 | approvedsource: Marketed | health-canada-dpd |